DK1687066T3 - Fremgangsmåder til immunmodulering - Google Patents

Fremgangsmåder til immunmodulering

Info

Publication number
DK1687066T3
DK1687066T3 DK04810895.5T DK04810895T DK1687066T3 DK 1687066 T3 DK1687066 T3 DK 1687066T3 DK 04810895 T DK04810895 T DK 04810895T DK 1687066 T3 DK1687066 T3 DK 1687066T3
Authority
DK
Denmark
Prior art keywords
immunomodulation
methods
Prior art date
Application number
DK04810895.5T
Other languages
English (en)
Inventor
Howard Weiner
Mohamed H Sayegh
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34623123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1687066(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK1687066T3 publication Critical patent/DK1687066T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04810895.5T 2003-11-14 2004-11-12 Fremgangsmåder til immunmodulering DK1687066T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52014803P 2003-11-14 2003-11-14
US56774104P 2004-05-03 2004-05-03
PCT/US2004/037910 WO2005048935A2 (en) 2003-11-14 2004-11-12 Methods of modulating immunity

Publications (1)

Publication Number Publication Date
DK1687066T3 true DK1687066T3 (da) 2012-11-26

Family

ID=34623123

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04810895.5T DK1687066T3 (da) 2003-11-14 2004-11-12 Fremgangsmåder til immunmodulering

Country Status (9)

Country Link
US (3) US7883703B2 (da)
EP (2) EP1687066B1 (da)
JP (1) JP5027512B2 (da)
AU (1) AU2004291107B2 (da)
CA (1) CA2545806C (da)
DK (1) DK1687066T3 (da)
ES (1) ES2393674T3 (da)
PL (1) PL1687066T3 (da)
WO (1) WO2005048935A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP1687066B1 (en) 2003-11-14 2012-08-29 Brigham and Women's Hospital, Inc. Methods of modulating immunity
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
AU2006267090B2 (en) * 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US20090258001A1 (en) * 2006-06-06 2009-10-15 Paul Ponath Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
MX2008015771A (es) * 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
JP2010508281A (ja) * 2006-10-26 2010-03-18 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション リン酸塩吸収の低減方法
EP2073827A4 (en) * 2006-11-03 2012-04-25 Univ Northwestern THERAPY FOR MULTIPLE SCLEROSIS
US20100015142A1 (en) * 2006-12-21 2010-01-21 Macrogenics Inc. Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
US20090131329A1 (en) * 2007-09-14 2009-05-21 Edmund John Miller Treatment for allograft rejection
EP2242513A2 (en) 2008-01-18 2010-10-27 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
NZ587901A (en) * 2008-03-13 2012-11-30 Immuron Ltd Immuno-modulating compositions for the treatment of immune-mediated disorders
EP2531216B1 (en) * 2010-02-04 2019-03-27 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
KR20130066626A (ko) * 2010-04-29 2013-06-20 나스벡스 엘티디. 항ｃｄ3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
US9587021B2 (en) 2011-05-21 2017-03-07 Macrogenics, Inc. CD3-binding molecules capable of binding to human and non-human CD3
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
US9701749B2 (en) * 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US20150132289A1 (en) * 2012-02-29 2015-05-14 Therapix Biosciences Ltd. Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
CA2915412A1 (en) 2012-06-14 2013-12-19 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
IL264502B2 (en) * 2016-08-29 2023-09-01 Tiziana Life Sciences Plc Anti-cd3 antibody formulations
TWI890481B (zh) 2018-02-09 2025-07-11 日商小野藥品工業股份有限公司 雙特異性抗體
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
DE102018213030A1 (de) 2018-08-03 2020-02-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN116406274B (zh) * 2020-07-30 2026-02-17 迪赞纳生命科学公开有限公司 用于治疗冠状病毒的cd3抗体
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
US20220332822A1 (en) * 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654210A (en) * 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4361549A (en) * 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4515893A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
CA1339070C (en) 1989-01-26 1997-07-29 Wulf Droge Treatment of diseases associated with cysteine deficiency
DE69032484D1 (de) 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ATE327331T1 (de) 1991-07-25 2006-06-15 Biogen Idec Inc Rekombinante antikörper zur humanen therapie
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5711937A (en) * 1993-06-28 1998-01-27 Lion Corporation Oral composition
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU729502B2 (en) * 1996-10-02 2001-02-01 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
WO2000062806A1 (en) * 1999-04-19 2000-10-26 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
WO2001094419A2 (en) 2000-06-07 2001-12-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method to induce the th1 immune response
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
JP2005500336A (ja) 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030094173A1 (en) * 2001-11-14 2003-05-22 Inhale Therapeutic Systems, Inc. Aerosolization device with improved endpiece connection
EP2034009B1 (en) * 2002-02-08 2014-01-15 Life Technologies Corporation Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation
WO2003068934A2 (en) 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
WO2003077834A2 (en) * 2002-03-15 2003-09-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
KR20050091713A (ko) * 2002-12-05 2005-09-15 프로테인 디자인 랩스 인코포레이티드 항-시디3 항체를 이용한 궤양성 대장염의 치료 방법
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
EP1687066B1 (en) * 2003-11-14 2012-08-29 Brigham and Women's Hospital, Inc. Methods of modulating immunity
IL172175A0 (en) * 2005-11-24 2011-08-01 Hadasit Med Res Service Beta glycolipids as immuno-modulators
EP2242513A2 (en) 2008-01-18 2010-10-27 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders

Also Published As

Publication number Publication date
AU2004291107B2 (en) 2010-09-30
ES2393674T3 (es) 2012-12-27
US20150064197A1 (en) 2015-03-05
US7883703B2 (en) 2011-02-08
EP2397189A1 (en) 2011-12-21
US9850305B2 (en) 2017-12-26
AU2004291107A1 (en) 2005-06-02
US20110165177A1 (en) 2011-07-07
EP1687066A4 (en) 2008-09-24
WO2005048935A3 (en) 2006-03-30
EP1687066A2 (en) 2006-08-09
CA2545806A1 (en) 2005-06-02
US20050196395A1 (en) 2005-09-08
EP2397189B1 (en) 2015-03-18
HK1098085A1 (en) 2007-07-13
WO2005048935A2 (en) 2005-06-02
CA2545806C (en) 2014-09-16
EP1687066B1 (en) 2012-08-29
JP2007511529A (ja) 2007-05-10
JP5027512B2 (ja) 2012-09-19
PL1687066T3 (pl) 2013-01-31

Similar Documents

Publication Publication Date Title
EP1583997A4 (en) Photoresist DISTANCE
DE502004010304D1 (de) Abdichtung
EP1745573A4 (en) PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
DE502004010381D1 (de) Um
NO20055459D0 (no) Prosesser
DK1691787T3 (da) Fremgangsmåde til at danne småpartikler
EP1650874A4 (en) Viterbi decoder
DE112004001791D2 (de) Bohrkopf
DE602004030875D1 (de) Duschkopf
DE502004005544D1 (de) Mikrodosiereinrichtung
NO20035626D0 (no) Metode
NO20035401D0 (no) Metode
DE502004008398D1 (de) Flachdichtung
DE112004002369D2 (de) Belag
FR2855730B1 (fr) Surmatelas de relaxation
DE502004000494D1 (de) Schrittschaltwerk
DE50301669D1 (de) Dichtring
EP1641929A4 (en) BLOSSOM TRANSFORMATION
FI20030461A0 (fi) Menetelmä hiihtää
NO20032626L (no) Teknisk ganghjelpemiddel
FI5943U1 (fi) Vesiallas
EE00391U1 (et) Ujulesta valmistamismeetod
FI20031551A0 (fi) Menetelmä rakentaa lumesta
SE0300751D0 (sv) Hjälpmedel
NO20035619D0 (no) Metode